Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
NeoAdj Chemo +/- Nivo MIBC
View
Description: A Phase 3 Randomized Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205 Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR PH 2 Enfortumab in Urothelial Pts-Cohort L
View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
PH3 Atez Bladder Can CTDNA+ (IMvigor)
View
Description: A PHASE III DOUBLE-BLIND MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY (BO42843)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph2 Sub Mosunetuzumab B-cell malig
View
Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Indication:
Blood Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
View
Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph 3 BYL719 + nabpax TNBC PIK3CA
View
Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 GDC-9545+ Palbo +/- Letro HER2- BC
View
Description: (BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
PH3 Tras Deru HER2- BC
View
Description: A Phase 3 Randomized Multi-center Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) (D9670C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4)
View
Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 Gem Carbo BC Preserve 2
View
Description: A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- BC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA
View
Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph2 Trila Sacit Gove TNBC
View
Description: A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph2 Tril early stg TNBC
View
Description: A Phase 2 Open-Label Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients with Early-Stage Triple Negative Breast Cancer (TNBC) (G1T28-212)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph3 Sac GOv vs PC BC
View
Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph1b AMG 510 MVASI Combo KRAS CRC
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ph3 Sinti vs Placebo ESCC
View
Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Gastric Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ
View
Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)
Indication:
Gastric Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1b AhRi BAY 2416964 + Pembro ST
View
Description: An open-label Phase 1b dose escalation and expansion study to evaluate the safety tolerability maximum tolerated or administered dose pharmacokinetics pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors (BAY 2416964 / 21343)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
View
Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Hematologic
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
PH3 Ven+G vs FCR/BR in Fit untreated CLL
View
Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ph3b ABL001 in CML-CP +/-T315i
View
Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III/IV
Title:
Ph3 Ascim vs PC TKI new dx Ph+ CML
View
Description: A phase III multi-center open-label randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301)
Indication:
Leukemia
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)
View
Description: D9103C00001: A Phase III Randomized Placebo-controlled Double-blind Multi-center International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph 3 Nivo+CCRT vs CCRT Durva la NSCLC
View
Description: CA20973L: A Phase 3 Randomized Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph 1 PF-06821497 R/R SCLC CRPC & FL
View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph3 SAR408701 vs Doce NSCLC CEACAM5+
View
Description: Randomized Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors (EFC15858)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph2 Nap r/r NSCLC
View
Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR PH3 JNJ-61186372 Peme EGFR NSCLC
View
Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph2 MRTX849 Pembro NSCLC KRAS
View
Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph2 Bren Vedo + Pembro ST prior PD-1
View
Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1b AhRi BAY 2416964 + Pembro ST
View
Description: An open-label Phase 1b dose escalation and expansion study to evaluate the safety tolerability maximum tolerated or administered dose pharmacokinetics pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors (BAY 2416964 / 21343)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1b AMG 510 in Combo NSCLC KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1b Sotora NSCLC KRAS p.G12C Brain Met
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1b AMG510 + Pembro NSCLC KRAS G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph2 Tomivosertib+Anti-PD-L1 NSCLC
View
Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
View
Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Biomarker status NSCLC
View
Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
View
Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR BV in pts w/1L cHL or PTCL
View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph 1 PF-06821497 R/R SCLC CRPC & FL
View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph3 Tafa+ Lena R-CHOP B-Cell Lymp
View
Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph3 LOXO-305 vs PC of BTK in MCL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph1/2 SINE KPT-8602 r/r MDS & AML
View
Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph2 Sub Mosunetuzumab B-cell malig
View
Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Melanoma
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph2 Bren Vedo + Pembro ST prior PD-1
View
Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)
Indication:
Melanoma
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Melanoma
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1/2 SINE KPT-8602 r/r MDS & AML
View
Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR Ph3 Navi Ruxo Myelofibrosis
View
Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Indication:
Myelofibrosis
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR Ph2 Selinexor vs PC MF
View
Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)
Indication:
Myelofibrosis
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1 SEA-BCMA R/R MM
View
Description: A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001)
Indication:
Myelomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
PH3 Dara/Len vs Len NDMM
View
Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)
Indication:
Myelomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Ph2 Dara Lena Dexa (DRd) MM I
View
Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)
Indication:
Myelomas
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
STAR Ph2 VS-6766 Fak-Inhib LGSOC
View
Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
PH2 CBP501 CIS NIVO PC WBC
View
Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph 1 PF-06821497 R/R SCLC CRPC & FL
View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Biomarker DNA Defect Men Prostate
View
Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Renal Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Skin Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph1/2 FIH BMS-986249 + Nivo Solid Tumor
View
Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors
View
Description: A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph 1 PF-06821497 R/R SCLC CRPC & FL
View
Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C
View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph2 Tumor-Agnostic Precision TAPISTRY
View
Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
STAR Ph2 Seribantumab NRG1 Fusion+ ST
View
Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph2 Bren Vedo + Pembro ST prior PD-1
View
Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Ph1b AMG 510 + Palboc ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
Phase 1/2a BMS-986253 + Nivo
View
Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
STAR PH 2 Enfortumab in Urothelial Pts-Cohort L
View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I/II
Title:
Ph1b AhRi BAY 2416964 + Pembro ST
View
Description: An open-label Phase 1b dose escalation and expansion study to evaluate the safety tolerability maximum tolerated or administered dose pharmacokinetics pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors (BAY 2416964 / 21343)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: I
Title:
A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR study)
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: III
Title:
Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II/III
Title:
A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Free Fatty Acid Supplementation on Aromatase in Obese Postmenopausal Women with Estrogen Receptor Positive Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: N/A
Title:
A phase 3, open-label, 3-cohort randomized study of N-803 in combination with current standard of care vs standard of care as first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Phase: II
Title:
EF-32 (TRIDENT): A PIVOTAL RANDOMIZED, OPEN-LABELSTUDY OF OPTUNE® (TTFIELDS, 200KHZ) CONCOMITANT WITHRADIATION THERAPY AND TEMOZOLOMIDE FOR THETREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
Evaluation of the Clinical Performance of the PAXgene Blood ccfDNA Tube in Comparison to the BD Vacutainer K2EDTA Tube Using the therascreen® PIK3CA RGQ PCR Kit
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE).
Indication:
Brain- Glioblastoma
Location:
Texas Oncology-Austin Brain Tumor Center
Title:
GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer.
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Brain Tumor Center